Overview of Coartem

Quick Facts

Property	Description
Active Ingredients	Artemether and Lumefantrine
Form	Fixed-Dose Combination (FDC) Tablets
Pharmacological Class	Antimalarial Drug / Blood Schizonticide
Common Use	Clearance of the Plasmodium falciparum parasite
Origin	Semisynthetic (Artemether) and Synthetic (Lumefantrine)

What is Artemether-Lumefantrine and its Pharmacological Class?

Artemether-Lumefantrine is a prescription fixed-dose combination (FDC) medicine classified as an antimalarial drug and a blood schizonticide. This classification reflects its primary role as a parasite-killing medicine designed to act specifically on the forms of the malaria parasite circulating in the blood. It is a cornerstone of the global strategy to treat malaria, representing a core Artemisinin-Based Combination Therapy (ACT) approach.

The FDC design is a key feature, as it enforces the simultaneous administration of two distinct active ingredients in a single tablet. This strategy minimizes the parasite's ability to develop resistance, as ACT is highly efficacious against multi-drug resistant P. falciparum malaria.

Composition, Origin, and Form of the Combination

The medicine is composed of the chemically distinct active agents Artemether and Lumefantrine, supplied as tablets for oral administration. Artemether is a fast-acting semisynthetic derivative of artemisinin, a compound originally derived from the Artemisia annua plant. Lumefantrine is the second component, a long-acting synthetic fluorene derivative developed specifically to clear residual parasites.

This unique combination of chemical classes, one rapid-onset and the other prolonged-action, provides a synergistic action that ensures the full and definitive clearance of the malaria parasite from the circulation.

Synergistic Action and General Therapeutic Purpose

The core principle behind this drug's effectiveness is its synergistic action, where both agents work together to achieve a comprehensive parasite-killing effect. Artemether's rapid action quickly reduces the parasite burden, while the sustained presence of Lumefantrine provides continuous coverage, preventing relapse. This combined mechanism has positioned the drug as a globally recommended first-line treatment for uncomplicated malaria.

Regulatory References

WHO Essential Medicines List

What side effects are possible with Coartem?

Possible Side Effects and Safety Information

Official regulatory documents classify the medicine's safety profile based on the frequency and system-organ class (SOC) of observed adverse reactions. The profile includes frequently observed effects on the Nervous System and Gastrointestinal tract, alongside specific constraints related to cardiovascular function and pre-existing conditions.

Adverse reactions are classified into frequency categories:

Very Common (occurring in ge 10% of individuals): Headache, dizziness, anorexia (decreased appetite), vomiting, abdominal pain, asthenia (weakness), arthralgia, myalgia, pyrexia, and cough.
Common (occurring in 1% to <10% of individuals): Palpitations, diarrhea, nausea, insomnia, rash, pruritus, fatigue, and QT interval prolongation on ECG.

Serious Safety Considerations

The most significant safety constraint involves the potential for QTc prolongation, an effect on the heart's electrical rhythm, which carries a risk of severe arrhythmias, including Torsade de Pointes. For this reason, official labeling contraindicates the medicine in individuals with a known history of QTc interval prolongation, symptomatic cardiac arrhythmias, clinically relevant bradycardia, or uncontrolled electrolyte disturbances (such as low potassium).

Specific caution is advised in individuals with severe hepatic or renal impairment, and monitoring of heart function and electrolyte levels may be required. Safety and effectiveness have not been established in non-immune children under 2 months of age or weighing less than 5 kg.

Overdose and Emergency Response

The official regulatory documents specify that an overdose of Artemether-Lumefantrine primarily carries a risk of severe cardiovascular and central nervous system toxicity. Documented manifestations may include the occurrence of heart rhythm problems such as a fast or irregular heartbeat, acute symptoms like seizure or fainting, and changes on an ECG, specifically QT interval prolongation. Serious, life-threatening outcomes associated with an overdose scenario include the potential for Torsade de pointes and sudden death.

Immediate emergency medical attention must be sought upon any suspicion of overdose or if severe symptoms, such as difficulty breathing or signs of a serious allergic reaction, occur. Regulators mandate that individuals call emergency services (911) immediately if the patient has collapsed, had a seizure, or cannot be awakened. Contacting the Poison Help line is also a required emergency action.

Management of an overdose, as described in regulatory information, involves standard medical procedures. No specific antidote is known. Treatment is restricted to symptomatic and supportive measures, including continuous ECG monitoring and correction of any electrolyte disturbances. Caution is advised when managing overdose in patients with severe hepatic or renal impairment, as the drug's effects may be magnified.

Therapeutic Uses of Coartem

What Artemether-Lumefantrine Treats: Main Uses and Benefits

The primary therapeutic objective involves addressing the root cause of acute, uncomplicated malaria caused by the Plasmodium falciparum parasite. This medicine is commonly used across conditions presenting with acute episodes of the infection, particularly in geographic regions where the parasite may be resistant to older antimalarial drugs. The use of this medication is considered relevant for the clearance of the parasite and supports management of the infection.

Symptom Management and Relief

The drug supports the management of symptoms related to systemic imbalance, which contributes to easing the overall symptom load. Specifically, it is applied in addressing symptom clusters that may become disruptive, such as high and persistent fever, debilitating chills, severe headache, and generalized muscle and joint pain. The medication contributes to improved comfort during periods of heightened symptoms. This approach is commonly used for managing the illness, assisting with the patient's systemic distress.

Quick Fact: Therapeutic Use

Quick Fact: Relief for Acute Febrile Symptoms : Is commonly used to help with symptoms related to systemic discomfort, including high fever and body aches, associated with acute malaria episodes.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Coartem (artemether/lumefantrine) is approved for the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum. Use is strictly defined by regulatory eligibility criteria and absolute contraindications.

Population Status	Eligibility Rule
Approved Minimum	Patients aged 2 months or older and weighing 5 kg or more [FDA/EMA].
Contraindicated	Patients with known hypersensitivity to components.
Contraindicated	History of QTc prolongation or electrolyte imbalances (e.g., hypokalemia).
Restricted Use	First trimester of pregnancy (not recommended if alternatives are available).
Restricted Use	Severe hepatic or renal impairment (caution advised due to limited data).
Not Approved	Treatment of severe or complicated malaria, or use for prevention (prophylaxis) of malaria.

The medicine is prohibited for patients with pre-existing cardiac conditions that prolong the QTc interval. While no dose adjustment is needed for mild-to-moderate renal or hepatic impairment, caution is necessary in severe impairment, as safety has not been established. Safety and efficacy are not established for infants weighing less than 5 kg.

What should I know about interactions with other medicines?

Coartem (artemether/lumefantrine) has officially documented interactions with other medicines and products that may affect its effectiveness or safety, or alter the levels of co-administered agents. Official regulatory documents establish specific restrictions related to these interactions.

Documented Interaction Constraints

Interacting Product Category	Constraint or Requirement
Other QTc-Prolonging Drugs	Co-administration is generally contraindicated or requires extreme caution, as the effects on the QTc interval may be additive, increasing the risk of serious cardiac rhythm abnormalities. This includes Class IA and III antiarrhythmics, neuroleptics, certain antidepressants and antibiotics (macrolides, fluoroquinolones), and other antimalarials like Halofantrine.
Strong CYP3A4 Inducers	Use is contraindicated due to the risk of significantly decreased plasma concentrations of artemether and lumefantrine, potentially leading to treatment failure. Examples include Rifampicin, Phenytoin, Carbamazepine, and the herbal product St. John’s wort (Hypericum perforatum).
Hormonal Contraceptives	Coartem may reduce the effectiveness of hormonal contraceptives. An additional non-hormonal method of birth control is required for women using these products.
Grapefruit Juice	Consumption of grapefruit juice is advised against as it may increase the levels of Coartem components in the blood, potentially increasing the risk of QTc prolongation.
Other Antimalarials	The combination should be avoided unless no other treatment option is available. If taken following Mefloquine, food consumption is encouraged due to a possible decrease in lumefantrine absorption. Halofantrine should not be administered for one month after Coartem due to its long half-life and the potential for additive QTc effects.

Mechanism of Action

The mechanism of Artemether-Lumefantrine involves the synergistic action of two distinct antiparasitic mechanisms that achieve the complete destruction of the blood-stage parasite.

Rapid Oxidative Attack on Parasite Cells

The Artemether component initiates a rapid, iron-catalyzed chemical reaction within the parasite's digestive vacuole. The iron (Ferrous Heme) cleaves Artemether's endoperoxide bridge, generating highly destructive free radicals and inhibiting the parasite's calcium pump (PfATP6). This leads to acute cellular damage and rapid reduction of the parasitic biomass.

Sustained Toxicity via Waste Detoxification Blockade

The Lumefantrine component acts by binding directly to the toxic free Heme, a byproduct of parasite hemoglobin digestion. By inhibiting the parasite's ability to convert this toxic Heme into harmless Hemozoin, Lumefantrine causes the accumulation of cytotoxic waste. This prolonged toxicity maintains sustained antiparasitic pressure on any remaining or slow-growing organisms.

Synergy for Comprehensive Parasite Clearance

The two mechanisms are complementary: the fast action of Artemether swiftly reduces the parasite load, while the prolonged action of Lumefantrine contributes to comprehensive parasite clearance. This mechanistic cooperation reduces the biological window for drug resistance to emerge. The mechanism is specifically active against the asexual blood-stage parasites and does not target the liver stages.

Dosage and Administration Information

Administration Guidelines

Artemether-Lumefantrine is administered via the oral route as a fixed-dose combination tablet. The medicine's use is structured as a fixed, short-term course spanning 3 days and consisting of six doses.

Dosing and Schedule

The standard dosing regimen for adults and pediatric patients weighing 35 kg or more requires the administration of four tablets per dose (80 mg Artemether/480 mg Lumefantrine). The total 6-dose course is initiated with the first dose, followed by a second dose 8 hours later on Day 1. The remaining four doses are administered twice daily on Day 2 and Day 3, completing the treatment schedule. For children weighing less than 35 kg, weight-based tiered dosing is applied to ensure appropriate drug exposure.

Administration Conditions

A critical administration instruction is that all doses must be taken with food or a fatty/milky drink. This condition is essential for the adequate systemic absorption of the Lumefantrine component. If a dose is vomited within 1 hour of administration, the dose should be repeated. The tablets can be crushed and mixed with a small amount of water for immediate consumption by patients who cannot swallow whole tablets. Furthermore, no dose adjustments are typically required for patients with mild to moderate hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coartem

Evidence for Use in Acute, Uncomplicated Plasmodium falciparum Malaria

The clinical evidence for Artemether-Lumefantrine (AL) is supported by numerous Randomized Controlled Trials (RCTs) and continuous Therapeutic Efficacy Studies (TES) conducted across various malaria-endemic regions. These studies included adults, adolescents, and children weighing 5 kg or more with uncomplicated Plasmodium falciparum infection. Researchers explored how symptoms change over time and monitored outcomes related to systemic imbalance by measuring the time required for parasite clearance from the bloodstream.

Studies measured the Adequate Clinical and Parasitological Response (ACPR) rate after a defined interval. Comparative trials also researched how the drug was evaluated against older treatments in research examining regions with reduced sensitivity to older treatments. However, there is limited information for long-term outcomes, as the follow-up durations were typically limited to 28 or 42 days.

Evidence for Use in Special Populations: Children, Pregnancy, and Co-morbidities

This block outlines the targeted research that has specifically assessed the drug in groups that may have altered drug exposure patterns, including infants, pregnant women during later trimesters, and patients co-infected with HIV receiving antiretroviral therapy.

Research on Infants and Low-Weight Children

Research explored the use of AL in a very specific group: infants and neonates weighing less than 5 kg. Studies primarily used Pharmacokinetic (PK) studies to measure drug concentrations in the blood. Studies reported measured ACPR rates related to parasite clearance in this population. The evidence remains limited, as the study volume is smaller compared to that of older children.

Research in Pregnancy and HIV Co-infection

Studies were conducted on pregnant women in their second and third trimesters. PK studies consistently reported a pattern of lower measured blood concentrations of the lumefantrine component in pregnant women compared to non-pregnant adults. This observation raises questions regarding the duration of drug exposure and its potential association with the durability of the parasite clearance. Research also included PK studies examining co-administration with Antiretroviral Therapy (ART) in HIV-co-infected patients, noting measured changes in plasma concentrations of both drugs.

Evidence Gaps and Areas of Ongoing Research

Continuous surveillance is necessary because parasite resistance patterns can evolve and are associated with measured changes in parasite clearance times in different regions. Another key limitation involves pharmacokinetic variability. Data for certain groups remain insufficient, and research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Coartem (FAQ)

Q: Why is Coartem sometimes given to people who travel?

According to global health guidance, this medicine is approved only for the treatment of acute, uncomplicated malaria. Official product information states that it is not approved for preventing malaria, also known as prophylaxis. Its use in regions where malaria is common is based on its classification as a globally recommended, first-line treatment.

Q: How long does it usually take to feel better after starting Coartem?

Clinical studies show that the artemether component of the medicine acts quickly. This rapid action is associated with a rapid reduction in parasite burden, which contributes to symptom improvement. However, official information does not provide a guaranteed or specific timeframe for when an individual patient will subjectively feel better.

Q: What if a dose of Coartem is missed or forgotten?

Official patient information states that if a dose is missed, it should be taken as soon as it is remembered. However, official instructions state that a double or extra dose should not be taken to catch up if it is almost time for the next scheduled dose. Regulatory guidance emphasizes that the entire 3-day treatment course should be completed to achieve comprehensive parasite clearance.

Q: How long do the active ingredients stay in the body after finishing the treatment?

The two ingredients have different durations in the body. The lumefantrine component, which is responsible for sustained parasite clearance, has a long elimination half-life, typically measured as three to six days in patients with malaria. The artemether component is cleared from the body much more quickly. This prolonged presence of lumefantrine is intended to help prevent the infection from returning.

Q: Does Coartem require a prescription in most places?

Yes, Coartem is officially classified as a prescription medicine. It is a fixed-dose combination drug that is dispensed under the guidance and authorization of a healthcare professional in most regions where it is used.

Q: How does Coartem compare to quinine in terms of general use?

Regulatory warnings mention that the use of quinine, another antimalarial drug, and other medicines that can affect the heart's rhythm (QTc-prolonging drugs) should be used with caution following Coartem treatment. This caution is due to the long half-life of lumefantrine and the potential for these effects to be combined, which is a recognized safety constraint.

Q: What happens if Coartem treatment is not completed?

Regulatory and patient information states that the entire course of the medicine should be completed exactly as prescribed by the healthcare provider. Finishing the entire regimen is necessary to achieve the intended parasite-killing effect and to prevent the potential return of the parasite infection.

Q: Are there any restrictions on activity while taking Coartem?

Official safety documents list common side effects such as dizziness and fatigue. Because of these potential nervous system effects, caution is described as necessary when performing activities like driving or operating machinery.

Q: Are there specific symptoms that signal a need for urgent medical attention while taking Coartem?

Official patient information advises seeking immediate medical help if a person experiences certain serious symptoms. These symptoms include severe dizziness, fainting, or changes to the heart rhythm, as documented in official warnings.

Q: Are there any known issues with taking Coartem with routine vitamins or supplements?

Regulatory documents provide a specific warning about the herbal product St. John’s wort (a supplement that can affect how the body breaks down drugs). However, official prescribing information does not generally list specific interactions with common non-herbal vitamins or mineral supplements.

Q: Can someone take Coartem if they have an allergy to other malaria drugs?

Official regulatory documents state that the medicine is strictly contraindicated (should not be used) only for patients with a known hypersensitivity, or allergy, to the active ingredients Artemether or Lumefantrine, or to any of the inactive components of the tablet. There is no general contraindication listed for allergies to other malaria drugs.

Q: What warnings are listed regarding Coartem and certain mental health conditions?

The official label describes warnings regarding interactions with other medications used to treat psychiatric conditions. Co-administration is contraindicated or requires caution with certain neuroleptics and specific antidepressant agents because of the risk of potential additive effects on the heart's QTc interval.

Q: What is the authorized use of Coartem in different countries?

Globally, the drug is indicated and authorized for the treatment of acute, uncomplicated malaria caused by the Plasmodium falciparum parasite only. Official documents do not typically authorize its use for other species of malaria or for severe or complicated cases.

Q: What percentage of people experience serious side effects with Coartem?

Official safety data lists the side effect of QT interval prolongation (an effect on the heart's electrical rhythm) as Common, meaning it occurs in 1% to less than 10% of individuals. While the risk of the most serious cardiac complication, Torsade de Pointes, is discussed as a major safety constraint, the frequency of this life-threatening event is not typically provided in the common frequency lists.

Q: Are the side effects of Coartem generally mild or severe?

Most commonly reported side effects, such as headache, dizziness, and vomiting, are typically described as mild. However, the official safety profile includes warnings about serious potential effects, primarily related to the heart's rhythm, which are listed as safety constraints.

Q: Does Coartem interact with common cold or flu medications?

The official label does not specifically name common cold or flu medicines, but it states that caution is needed with drugs that affect the heart's electrical rhythm (QTc prolonging drugs). This can include certain antibiotics (like macrolides or fluoroquinolones) that may sometimes be used to treat infections related to a cold or flu.

Q: What is the shelf life of Coartem tablets?

Official regulatory documents often indicate that the tablets are manufactured with a shelf-life of approximately two years from the date of manufacture. The medicine must be stored correctly at controlled room temperature and protected from heat and moisture to maintain its stability throughout its shelf life.

How should Coartem be stored and disposed of?

Storage Requirements

Coartem tablets must be stored at controlled room temperature, which ranges from 20 C to 25 C (68 F to 77 F). The product must be kept from freezing and protected from heat, moisture, and light to maintain its stability. Regulatory instructions specify that the medicine must be stored in its original container and the container must be kept tightly closed.

Child Safety and Disposal

The tablets must always be stored out of the reach of children.

Disposal of any unused or expired Coartem must follow regulatory guidelines. The medicine must not be discarded in household waste or wastewater. Patients are instructed to consult a healthcare professional to ensure proper disposal according to local pharmaceutical waste handling requirements.

Coartem